Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) today announced the initiation of a Phase 2 dose-ranging trial of a fixed-dose combination (FDC) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE